The FDA has launched the Adverse Event Monitoring System (AEMS), a unified platform consolidating disparate reporting systems for drugs, devices, food, cosmetics, vaccines, and more.12467
AEMS replaces outdated, fragmented systems to improve data access, aggregation, and research opportunities, with a single dashboard for adverse event reports.24
The system aims to save $120 million by reducing administrative burdens and enhancing efficiency with AI tools and advanced analytics.1
FDA Commissioner Marty Makary stated the previous systems wasted taxpayer dollars and created surveillance blind spots.2
Full real-time reporting for all FDA-regulated products will be available by the end of May 2026, protecting patient privacy.23
Electronic submission standards like E2B(R3) have implementation deadlines of April 1, 2026, for various reports.45
Sources:
1. https://www.fiercepharma.com/pharma/fda-rolls-out-new-streamlined-adverse-event-monitoring-system
2. https://www.unmc.edu/healthsecurity/transmission/2026/03/11/fda-launches-new-combined-adverse-event-database/
3. https://www.auntminnie.com/practice-management/administration/risk-management/news/15819348/fda-moves-to-quickly-replace-adverse-event-reporters
4. https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-electronic-submissions
5. https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submissions
6. https://www.pharmaceuticalcommerce.com/view/fda-vowes-improved-adverse-event-reporting-with-aems
7. https://www.raps.org/news-and-articles/news-articles/2026/3/fda-consolidates-adverse-events-reporting-systems